November, 2024
November 2024
M T W T F S S
 123
45678910
11121314151617
18192021222324
252627282930  
The MARGOT is optimizing preoperative therapy for Stage II-III HER2+ breast cancer – Dana-Farber’s Breast Oncology Center
Feb 15, 2024, 18:29

The MARGOT is optimizing preoperative therapy for Stage II-III HER2+ breast cancer – Dana-Farber’s Breast Oncology Center

Dana-Farber’s Breast Oncology Center shared a post on X/Twitter:

The MARGOT study led by Dana-Farber’s Breast Oncology Center and Translational Breast Cancer Research Consortium is optimizing preoperative therapy for Stage II-III HER2+ breast cancer, comparing paclitaxel/margetuximab/pertuzumab to paclitaxel/trastuzumab/pertuzumab. For more information call 877-338-7425 or visit the website.

Source: Dana-Farber’s Breast Oncology Center/X